156 related articles for article (PubMed ID: 21436358)
21. Respiratory tract infections in the immunocompromised.
Godbole G; Gant V
Curr Opin Pulm Med; 2013 May; 19(3):244-50. PubMed ID: 23508112
[TBL] [Abstract][Full Text] [Related]
22. Extensively Drug-Resistant Tuberculosis: Principles of Resistance, Diagnosis, and Management.
Wilson JW; Tsukayama DT
Mayo Clin Proc; 2016 Apr; 91(4):482-95. PubMed ID: 26906649
[TBL] [Abstract][Full Text] [Related]
23. Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.
Kempker RR; Kipiani M; Mirtskhulava V; Tukvadze N; Magee MJ; Blumberg HM
Emerg Infect Dis; 2015 Jun; 21(6):992-1001. PubMed ID: 25993036
[TBL] [Abstract][Full Text] [Related]
24. Barriers to the effective management of respiratory tract infections in the community.
Saginur R
Infection; 2001 Dec; 29 Suppl 2():3-10. PubMed ID: 11785853
[TBL] [Abstract][Full Text] [Related]
25. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections.
Amaral L; Viveiros M
Int J Antimicrob Agents; 2012 May; 39(5):376-80. PubMed ID: 22445204
[TBL] [Abstract][Full Text] [Related]
26. [Guidelines for the epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults].
Höffken G; Lorenz J; Kern W; Welte T; Bauer T; Dalhoff K; Dietrich E; Ewig S; Gastmeier P; Grabein B; Halle E; Kolditz M; Marre R; Sitter H
Dtsch Med Wochenschr; 2010 Feb; 135(8):359-65. PubMed ID: 20166002
[No Abstract] [Full Text] [Related]
27. [Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany].
Höffken G; Lorenz J; Kern W; Welte T; Bauer T; Dalhoff K; Dietrich E; Ewig S; Gastmeier P; Grabein B; Halle E; Kolditz M; Marre R; Sitter H; ; ;
Pneumologie; 2009 Oct; 63(10):e1-68. PubMed ID: 19821215
[No Abstract] [Full Text] [Related]
28. Treatment of chronic respiratory infections.
Burns MW
Drugs; 1979 Jul; 18(1):58-64. PubMed ID: 477574
[No Abstract] [Full Text] [Related]
29. [Management of lower respiratory tract infections in immunocompetent adults (community-acquired pneumonia and acute exacerbation of chronic obstructive pulmonary disease): the challenge of a new consensus conference].
Chidiac C
Med Mal Infect; 2006 Jan; 36(1):1-3. PubMed ID: 16413722
[No Abstract] [Full Text] [Related]
30. Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations.
Tokman S; Schuetz P; Bent S
Expert Rev Anti Infect Ther; 2011 Jun; 9(6):727-35. PubMed ID: 21692680
[TBL] [Abstract][Full Text] [Related]
31. Nocardia cyriacigeorgica in an immunocompetent patient.
Kibe S; Meigh R; Moon T; Kastelik J; Morjaria J
Ther Adv Respir Dis; 2015 Feb; 9(1):28-30. PubMed ID: 25583961
[No Abstract] [Full Text] [Related]
32. The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung inflammation and epithelial damage.
Di Marco F; Braido F; Santus P; Scichilone N; Blasi F
Eur Rev Med Pharmacol Sci; 2014; 18(3):321-32. PubMed ID: 24563430
[TBL] [Abstract][Full Text] [Related]
33. Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination.
Koenig R
Science; 2008 Feb; 319(5865):894-7. PubMed ID: 18276863
[No Abstract] [Full Text] [Related]
34. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
[TBL] [Abstract][Full Text] [Related]
35. Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.
Kurbatova EV; Dalton T; Ershova J; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Cegielski JP
Emerg Infect Dis; 2015 Jun; 21(6):977-83. PubMed ID: 25988299
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators.
Christ-Crain M; Müller B
Eur Respir J; 2007 Sep; 30(3):556-73. PubMed ID: 17766633
[TBL] [Abstract][Full Text] [Related]
37. Clinical management of respiratory tract infections in the community: experience with telithromycin.
Quintiliani R
Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
[TBL] [Abstract][Full Text] [Related]
38. Short-duration therapy for respiratory tract infections.
Goff DA
Ann Pharmacother; 2004 Sep; 38(9 Suppl):S19-23. PubMed ID: 15226490
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
40. Which patients with respiratory disease need long-term azithromycin?
Alchakaki A; Cramer C; Patterson A; Soubani AO
Cleve Clin J Med; 2017 Oct; 84(10):755-758. PubMed ID: 28985171
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
